- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
Phospho-ELK1-S389 AntibodyPeptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP3377a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
Phospho-ELK1-S389 Antibody - Product info | |
| Application | DB
|
| Primary Accession | P19419 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 44888 Da |
Phospho-ELK1-S389 Antibody - Additional info | |
| Gene ID 2002 | |
| Other Names ELK1; ETS domain-containing protein Elk-1 | |
| Target/Specificity This Phospho-ELK1-S389 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding S389 of human ELK1. | |
| Dilution DB~~1:100~500 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is first purified by protein A affinity chromatography. Then, the antibody fraction is peptide affinity purified in a 2-step procedure with peptides. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions Phospho-ELK1-S389 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. | |
Phospho-ELK1-S389 Antibody - Protein Information | |
| Name ELK1 | |
| Function Stimulates transcription. Binds to purine-rich DNA sequences. Can form a ternary complex with the serum response factor and the ETS and SRF motifs of the fos serum response element | |
| Cellular Location Nucleus. | |
| Tissue Location Lung and testis. | |
Phospho-ELK1-S389 Antibody - Related products
AP3309a: Phospho-ELK1-S383 Antibody
AP3377a: Phospho-ELK1-S389 Antibody
AP3424a: Phospho-ELK1-T417 Antibody
DC08031: Human ELK1 cDNA Clone
LY11846a: ELK1 Over-expression Lysate
BP3309a: Phospho-ELK1-S383 Antibody Blocking Peptide
BP3377a: Phospho-ELK1-S389 Antibody Blocking Peptide
BP3424a: Phospho-ELK1-T417 Antibody Blocking Peptide
BP6282a: ELK1 Antibody (S383) Blocking Peptide
Phospho-ELK1-S389 Antibody - Application data
-
Dot blot analysis of Phospho-ELK1-S389 Antibody (Cat. #AP3377a) and anti-ELK1 Non Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.
Phospho-ELK1-S389 Antibody - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
ELK1 is a member of the Ets family of transcription factors and of the ternary complex factor (TCF) subfamily. Proteins of the TCF subfamily form a ternary complex by binding to the the serum response factor and the serum reponse element in the promoter of the c-fos proto-oncogene. The protein is a nuclear target for the ras-raf-MAPK signaling cascade.
REFERENCES
Salinas, S., et al., J. Cell Biol. 165(6):767-773 (2004). Yang, S.H., et al., Mol. Cell 12(1):63-74 (2003). Bebien, M., et al., Oncogene 22(12):1836-1847 (2003). Sharrocks, A.D., Biochem. Soc. Trans. 30(2):1-9 (2002). Murai, K., et al., Mol. Cell. Biol. 22(20):7083-7092 (2002).